Hematuria differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 126: Line 126:
{|
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="7" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
|-
|-
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 1
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Low back pain
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 2
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptom 3
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nausea/Vomiting
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 1
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Urinary symptoms
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hypertension
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pitting edema
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 1
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 2
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab 3
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Biomarkers
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 1
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Urinalysis
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 2
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Ultrasonography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 3
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CT scan
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysuria
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Frequency
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Oliguria
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Light microscopy
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Electron microscopy
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunoflourescence pattern
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 1
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 1
Line 156: Line 164:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 166: Line 177:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 173: Line 186:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 183: Line 199:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 190: Line 208:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 200: Line 221:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 207: Line 230:
! colspan="1" rowspan="1" |Symptom 2
! colspan="1" rowspan="1" |Symptom 2
!Symptom 3
!Symptom 3
!
!
!
!Physical exam 1
!Physical exam 1
! colspan="1" rowspan="1" |Physical exam 2
! colspan="1" rowspan="1" |Physical exam 2
Line 217: Line 243:
!Imaging 3
!Imaging 3
!Histopathology
!Histopathology
!
!
|'''Gold standard'''
|'''Gold standard'''
!Additional findings
!Additional findings
Line 224: Line 252:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 234: Line 265:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 241: Line 274:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 251: Line 287:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 258: Line 296:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 268: Line 309:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|
|
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 20:50, 3 May 2018

Hematuria Microchapters

Home

Patient Information

Overview

Definition

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hematuria from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hematuria differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hematuria differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hematuria differential diagnosis

CDC on Hematuria differential diagnosis

Hematuria differential diagnosis in the news

Blogs on Hematuria differential diagnosis

Directions to Hospitals Treating Hematuria

Risk calculators and risk factors for Hematuria differential diagnosis

Steven C. Campbell, M.D., Ph.D. Associate Editor(s)-in-Chief: Venkata Sivakrishna Kumar Pulivarthi M.B.B.S [1]

Overview

Gross hematuria(GH) must be distinguished from pigmenturia, which may be due to endogenous sources (e.g., bilirubin, myoglobin, porphyrins), foods ingested (e.g., beets and rhubarb), drugs (e.g., phenazopyridine), and simple dehydration. This distinction can be made easily by urinalysis with microscopy. Notably, myoglobinuria and other factors can cause false-positive chemical tests for hemoglobin, so urine microscopy is required to confirm the diagnosis of hematuria. GH also must be distinguished from vaginal bleeding in women, which usually can be achieved by obtaining a careful menstrual history, collecting the specimen when the patient is not having menstrual or gynecologic bleeding, or, if necessary, obtaining a catheterized specimen. GH may also be detected by the presence of blood spotting on the undergarments of incontinent patients. After ruling out vaginal bleeding and mimics of hematuria, a urologic source must be suspected.

Differential Diagnosis

Hematuria should be differentiated from other disease which mimic hematuria especially hemoglobinuria and myoglobinuria which are dipstick positive but negative for microscopy.

Differentiating Hemoglobinuria from Myoglobinuria

 
 
 
 
 
 
 
Centrifuse Result
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sediment Red
 
 
 
 
 
 
 
Supernatant Red
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hematuria
 
 
 
 
 
 
 
Dipstick heme
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Negative
 
 
 
 
Positive
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Beeturia
❑ Phenazopyridine
❑ Porphyria
❑ Other
 
 
 
 
❑ Myoglobin
❑ Hemoglobin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma color
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clear
 
 
 
 
 
Red
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myoglobinuria
 
 
 
 
 
Hemoglobinuria
CATEGORY[1] EXAMPLES COMMON CLINICAL PRESENTATION AND RISK FACTORS
Neoplasm
Any
Male gender, Age older than 35 years, Past or current smoking history, Occupational or other exposure to chemicals or dyes (benzenes or aromatic amines), Analgesic abuse, History of gross hematuria, History of urologic disorder or disease, History of Irritative voiding symptoms, History of pelvic irradiation, History of chronic urinary tract infection, Exposure to known carcinogenic agents or chemotherapy such as alkylating agents, History of chronic indwelling foreign body
Bladder cancer
Older age, male predominance, tobacco, occupational exposures, Irritative voiding symptoms
Ureteral or renal pelvis cancer
Family history of early colon cancers or upper tract tumors, flank pain
Renal cortical tumor
Family history of early kidney tumors, flank pain, flank mass
Prostate cancer
Older age, family history, African-American
Urethral cancer
Obstructive symptoms, pain, bloody discharge
Infection/inflammation
Any
History of infection
Cystitis
Female predominance, dysuria
Pyelonephritis
Fever, flank pain, diabetes, female predominance
Urethritis
Exposure to sexually transmitted infections, urethral discharge, dysuria
Tuberculosis
Travel to endemic areas
Schistosomiasis
Travel to endemic areas
Calculus
Nephroureterolithiasis
Flank pain, family history, prior stone
Bladder stones
Bladder outlet obstruction
Prostatic cause
Benign prostatic enlargement
Male, older age, obstructive symptoms
Medical renal disease
Any
Hypertension, azotemia, dysmorphic erythrocytes, cellular casts, proteinuria
IgA nephropathy
Upper respiratory tract infection, gastroenteritis, synchronous association of pharyngitis, children
Congenital or acquired anatomic abnormality
Polycystic kidney disease Family history of renal cystic disease
Uretero-pelvic junction obstruction History of UTI, stone, flank pain
Ureteral stricture History of surgery or radiation, flank pain, hydronephrosis; stranguria, spraying urine
Urethral diverticulum Discharge, dribbling, dyspareunia, history of UTI, female predominance
Fistula Pneumaturia, Fecaluria, abdominal pain, recurrent UTI, history of diverticulitis or colon cancer
Other
Exercise-induced hematuria
Recent vigorous exercise
Endometriosis
Cyclic hematuria in a menstruating woman
Hematologic or thrombotic disease
Family history of personal history of bleeding or thrombosis
Papillary necrosis
African-American, sickle cell disease, diabetes, analgesic abuse
Interstitial cystitis
Voiding symptoms

Hematuria differential diagnosis

Differentiating the diseases that can cause hematuria:

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Low back pain Fever Nausea/Vomiting Urinary symptoms Hypertension Pitting edema Other CBC Biomarkers Urinalysis Ultrasonography CT scan Other
Dysuria Frequency Oliguria Light microscopy Electron microscopy Immunoflourescence pattern
Differential Diagnosis 1
Differential Diagnosis 2
Differential Diagnosis 3
Diseases Symptom 1 Symptom 2 Symptom 3 Physical exam 1 Physical exam 2 Physical exam 3 Lab 1 Lab 2 Lab 3 Imaging 1 Imaging 2 Imaging 3 Histopathology Gold standard Additional findings
Differential Diagnosis 4
Differential Diagnosis 5
Differential Diagnosis 6
Gross hematuria Causes of hematuria Sub-entity Causes and associations History and Symtoms Laboratory Findings
History Shaking, chills and rigors Fever Nausea/vomiting Dysuria Frequency Pitting edema Hypertension Hemoptysis Oliguria Peri-orbital edema (Facial puffiness) Urinalysis Cystoscopy Hyperlipidemia and hypercholesterolemia Nephrotic features Nephritic features ANCA Anti-glomerular basement membrane antibody (Anti-GBM antibody) Immune complex formation Light microscope Electron microscope Immunoflourescence pattern
Urolithiasis (Renal stones)- may be microscopic
  • Calcium oxalate stones
  • Calcium phosphate stones
  • Uric acid stones
  • Magnesium ammonium phosphate stones
  • Cysteine stones
  • Low calcium diet
  • Hyperparathyroidism
  • Hypocalcemic hypercalciuria
  • Anatomic abnormalities of the urinary tract
  • Obesity
  • Dehydration
  • Diets rich in oxalate
  • Urinary tract infection
  • Increased or decreased urinary pH
  • Episodic lower back pain radiating to the groin
+/- +/- + + - - - - + -
  • > 5 RBCs/hpf (exaggerated in gross hematuria)
- - - - - - - - - -
Renal tumors- may be microscopic
Renal cysts
Prostatitis
Benign prostatic hyperplasia (BPH)- may be micrscopic
Anti-coagulant use- may be microscopic Oral anticoagulant use
Heparin
Aspirin
Clopidogrel
Ticlopidine
Factor Xa inhibitors
Bladder tumors- may be micrscopic Transitional cell carcinoma
  • Male sex
  • Past or current smoking
  • Exposure to known carcinogenic agents or alkylating chemotherapeutic agents
  • Age older than 35 years
  • Exposure to chemicals or dyes (benzenes or aromatic amines)
  • Chronic indwelling foreign body
  • Chronic urinary tract infection
  • Pelvic irradiation
- - +/- +/- - - - - -
Urinary tract infection- may be microscopic
Tuberculosis
Schistomsomiasis
Hemorrhagic cystitis
Renal infarction
Recent urologic procedure
Microscopic hematuria Glomerulonephritides Non-proliferative Minimal change disease
  • Idiopathic
  • Protein tyrosine phosphatase receptor type O (glomerular epithelial protein 1- GLEPP1)
  • Young children
  • Recent infection and immunization
  • Atopy
  • Hodgkin lymphoma
  • Thrombosis (due to urinary loss of antithrombin-III)
+ - - +/- - + + - - - -
  • Normal
  • Fusion of podocytes
-
Focal segmental glomerulosclerosis
  • Idiopathic
  • HIV
  • Heroine use
  • Sickle cell disease
  • Interferon
  • Severe obesity
  • Mixed cryoglobunemia (Hepatitis C)
  • Adults
+ - - +/- - + + - - - -
  • Focal (some glomeruli) and segmental (only part of glomerulus)
  • Effacement of podocytes
-
Membranous glomerulonephritis
  • Idiopathic
  • Hepatitis B and C
  • Solid tumors
  • Systemic lupus erythmatosus
  • Drugs (NSAIDS, penclliamine, gold, captopril)
+ - - +/- - + + - - - +
  • Thick glomerular basement membrance
  • Sub-epithelial immune complex depositis with 'spike and dome' appearance
-
Proliferative IgA nephropathy
  • Idiopathic
  • Viral infections
  • Young children
  • History of mucosal infections (e.g. gastroenteritis) and upper respiratory tract infection
  • 2-3 days after infection (synpharyngitic)
+/- + - + +/- - - + - - +
  • Crescent formation
  • Mesangial proliferation
-
Rapidly progressive glomerulonephritis
  • Goodpasture syndrome
  • Young adults
+/- + + + + - - + - + +
  • Hypercellular and inflamed glomeruli (Crescent formation)
  •  Diffuse thickening of the glomerular basement membrane with absence of subepithelial and subendothelial deposits 
+ (Linear)
  • Post infectious glomerulonephritis
  • Streptococcal skin infections
  • Streptococcal pharyngitis
  • 2-3 weeks after infection
+/- + + + + - - + - - +
  • Hypercellular and inflamed glomeruli
  • Sub-epithelial immune complex deposits
+ (Granular)
  • Granulomatosis with polyangitis (Wegner's granulomatosis)
+/- + + + + - - + + (C-ANCA) - -
  • Hypercellular and inflamed glomeruli (Crescent formation)
- (pauci-immune) +/-
  • Churg Strauss syndrome
  • Necrotizing granulomas (Lungs and kidneys)
  • Asthma
  • Peripheral neuropathy
+/- + + + + - - +

+ (C-ANCA)

- -
  • Hypercellular and inflamed glomeruli (Crescent formation)
- (pauci-immune) -
  • Microscopic polyngitis
  • Necrotizing vasculitis (no granuloma)
+/- + + + + - - +

+ (P-ANCA)

- -
  • Hypercellular and inflamed glomeruli (Crescent formation)
- (pauci-immune) -
Membranoproliferative glomerulonephritis
  • Idiopathic
  • Hepatitis B and C (Type 1)
  • C3 nepritic factor (Type2)
  • hematuria
  • Oliguria
  • Periorbital edema
  • Hypertension
+/- + + + + - + - - - +
  • Thick glomerular basement membrane (Tram-track appearance)
  • Mesangial proliferation and leukocyte infiltration
+ (Granular)
Henoch-Schonlein purpura
Alport's syndrome
Diabetic glomerulosclerosis
Interestitial nephritis
Renal papillary necrosis
Renal artery stenosis

References

  1. Wein, Alan (2016). Campbell-Walsh urology. Philadelphia, PA: Elsevier. ISBN 978-1455775675.

Template:WH Template:WS